About Viking Therapeutics
Viking Therapeutics is a company based in United States founded in 2012. Viking Therapeutics has raised $2.5 million across 1 funding round from investors including Ligand Pharmaceuticals. The company has 36 employees as of December 31, 2024. Viking Therapeutics offers products and services including VK2735, VK2809, VK0214, and VK5211. Viking Therapeutics operates in a competitive market with competitors including Neurocrine, Crinetics, Carmot, Zucara Therapeutics and MBX Biosciences, among others.
- Headquarter California, United States
- Employees 36 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Viking Therapeutics, Inc.
-
Annual Revenue
Not available
-
Net Profit
-$359.64 M (USD)-227.05as on Dec 31, 2025
-
EBITDA
-$392.91 M (USD)-160.94as on Dec 31, 2025
-
Total Equity Funding
$2.5 M (USD)
in 1 rounds
-
Latest Funding Round
$2.5 M (USD), Seed
May 22, 2014
- Investors
-
Employee Count
36
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Viking Therapeutics
Viking Therapeutics is a publicly listed company on the NASDAQ with ticker symbol VKTX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Viking Therapeutics
Viking Therapeutics offers a comprehensive portfolio of products and services, including VK2735, VK2809, VK0214, and VK5211.
Therapeutic for obesity and metabolic disorders via oral administration.
Treatment for NASH and related metabolic conditions.
Therapy for rare disease X-ALD.
addresses hip fracture and muscle wasting.
People of Viking Therapeutics
Unlock access to complete
Funding Insights of Viking Therapeutics
Viking Therapeutics has successfully raised a total of $2.5M through 1 strategic funding round. The most recent funding activity was a Seed round of $2.5 million completed in May 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Viking Therapeutics
Viking Therapeutics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Ligand Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Pharmaceutical drugs are manufactured and developed in the United States.
|
Locked | Locked | Locked |
Investor details for Viking Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Viking Therapeutics
Investment portfolio details for Viking Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Viking Therapeutics
Detailed financials for Viking Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Viking Therapeutics Comparisons
Peer comparison for Viking Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Viking Therapeutics
Viking Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Neurocrine, Crinetics, Carmot, Zucara Therapeutics and MBX Biosciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of small molecule therapeutics for endocrine and CNS disorders
|
|
| Locked | Locked | Locked |
Developer of therapies for the treatment of endocrine-related diseases and cancers
|
|
| Locked | Locked | Locked |
Disease-modifying therapies for metabolic diseases are developed.
|
|
| Locked | Locked | Locked |
Developing a long-term therapeutic approach to prevent hypoglycemia in patients with diabetes
|
|
| Locked | Locked | Locked |
Drugs for rare endocrine diseases are developed and advanced.
|
|
| Locked | Locked | Locked |
Protein therapies for diabetes and gastrointestinal diseases are developed.
|
Detailed competitors of Viking Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Viking Therapeutics
Complete news archive for Viking Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Viking Therapeutics
Viking Therapeutics was founded in 2012 and raised its 1st funding round 2 years after it was founded.
Viking Therapeutics is headquartered in United States. It is registered at California, United States.
Brian Lian is the current CEO of Viking Therapeutics.
Viking Therapeutics is a funded company, having raised a total of $2.5M across 1 funding round to date.
As of Dec 31, 2024, the latest employee count at Viking Therapeutics is 36.
Viking Therapeutics was founded in 2012 in California, United States, and operates in the biotechnology sector. A portfolio of five therapeutic programs based on small molecules is maintained, targeting endocrine and metabolic disorders. The lead candidate, VK0612, is an oral drug for type 2 diabetes, while VK5211 serves as a non-steroidal selective androgen receptor modulator for cancer cachexia. Three preclinical programs address metabolic diseases and anemia.
Viking Therapeutics's top competitors include Crinetics, Neurocrine and Zucara Therapeutics.
Viking Therapeutics offers VK2735, VK2809, VK0214, and VK5211.
Yes, Viking Therapeutics is publicly traded on NASDAQ under the ticker symbol VKTX.
Viking Therapeutics has 1 investor. Key investors include Ligand Pharmaceuticals.
The ticker symbol of Viking Therapeutics is VKTX on NASDAQ.